263 related articles for article (PubMed ID: 18537685)
1. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?
Feldman PL; Lambert MH; Henke BR
Curr Top Med Chem; 2008; 8(9):728-49. PubMed ID: 18537685
[TBL] [Abstract][Full Text] [Related]
2. Safety issues and prospects for future generations of PPAR modulators.
Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
[TBL] [Abstract][Full Text] [Related]
3. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
Yumuk VD
Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
[TBL] [Abstract][Full Text] [Related]
4. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
Mansour M
Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
[TBL] [Abstract][Full Text] [Related]
5. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Tenenbaum A; Motro M; Fisman EZ
Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
[TBL] [Abstract][Full Text] [Related]
6. Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases.
Balint BL; Nagy L
Endocr Metab Immune Disord Drug Targets; 2006 Mar; 6(1):33-43. PubMed ID: 16611163
[TBL] [Abstract][Full Text] [Related]
7. Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures.
Oyama T; Toyota K; Waku T; Hirakawa Y; Nagasawa N; Kasuga JI; Hashimoto Y; Miyachi H; Morikawa K
Acta Crystallogr D Biol Crystallogr; 2009 Aug; 65(Pt 8):786-95. PubMed ID: 19622862
[TBL] [Abstract][Full Text] [Related]
8. Evolution of peroxisome proliferator-activated receptor agonists.
Chang F; Jaber LA; Berlie HD; O'Connell MB
Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
[TBL] [Abstract][Full Text] [Related]
9. [Nuclear receptors PPAR as a drug target in metabolic disorders].
Stolarczyk M; Gutman W; Derlacz RA
Postepy Biochem; 2011; 57(2):207-14. PubMed ID: 21913422
[TBL] [Abstract][Full Text] [Related]
10. PPARs as targets for metabolic and cardiovascular diseases.
Cheng PT; Mukherjee R
Mini Rev Med Chem; 2005 Aug; 5(8):741-53. PubMed ID: 16101410
[TBL] [Abstract][Full Text] [Related]
11. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.
Hong F; Xu P; Zhai Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060458
[TBL] [Abstract][Full Text] [Related]
12. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications.
Mirza AZ; Althagafi II; Shamshad H
Eur J Med Chem; 2019 Mar; 166():502-513. PubMed ID: 30739829
[TBL] [Abstract][Full Text] [Related]
13. The next generation of PPAR drugs: do we have the tools to find them?
Shearer BG; Billin AN
Biochim Biophys Acta; 2007 Aug; 1771(8):1082-93. PubMed ID: 17602866
[TBL] [Abstract][Full Text] [Related]
14. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
15. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
Gross B; Staels B
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
[TBL] [Abstract][Full Text] [Related]
16. Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors.
Miyachi H
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502131
[TBL] [Abstract][Full Text] [Related]
17. PPARs: therapeutic targets for metabolic disease.
Berger JP; Akiyama TE; Meinke PT
Trends Pharmacol Sci; 2005 May; 26(5):244-51. PubMed ID: 15860371
[TBL] [Abstract][Full Text] [Related]
18. Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease.
Bisgaier CL; Oniciu DC; Srivastava RAK
J Cardiovasc Pharmacol; 2018 Jul; 72(1):3-10. PubMed ID: 29621036
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
Brown JD; Plutzky J
Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
[TBL] [Abstract][Full Text] [Related]
20. Nuclear receptors of the peroxisome proliferator-activated receptor (PPAR) family in gestational diabetes: from animal models to clinical trials.
Arck P; Toth B; Pestka A; Jeschke U
Biol Reprod; 2010 Aug; 83(2):168-76. PubMed ID: 20427759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
